RxDoctor Payments Data

Tanmay Swadia, MD

Interventional Cardiology · Ypsilanti, MINPI 1265694426

Payments from drug & device makers

$2,669in general payments, 2019–2025

Across 84 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$773
  • Penumbra, Inc.$768
  • Abbott$309
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$145
  • Cordis US CORP.$107
  • Inari Medical, Inc.$105
  • plus $464 from 18 others

What the payments were for

  • Food & beverage$2,669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,669 in reported general payments places this provider in the 20th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$134,799
Medicare patients
1,284
Services billed
2,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$277,826
XareltoRivaroxaban57$68,046
Repatha SureclickEvolocumab38$44,454
JardianceEmpagliflozin15$21,973
Repatha SyringeEvolocumab15$18,200
Atorvastatin Calcium267$4,646
Ranolazine ErRanolazine17$4,048
Metoprolol Succinate175$3,167
Bisoprolol Fumarate24$1,996
Losartan Potassium105$1,420
ClopidogrelClopidogrel Bisulfate74$1,400
Rosuvastatin Calcium71$1,141
Carvedilol83$1,138
Isosorbide Mononitrate ErIsosorbide Mononitrate40$1,120
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$277,826207 claims
Johnson & JohnsonXarelto$15$68,04657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →